Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 1;10(5):516.
doi: 10.3390/antibiotics10050516.

Use of Procalcitonin during the First Wave of COVID-19 in the Acute NHS Hospitals: A Retrospective Observational Study

Affiliations

Use of Procalcitonin during the First Wave of COVID-19 in the Acute NHS Hospitals: A Retrospective Observational Study

Neil Powell et al. Antibiotics (Basel). .

Abstract

A minority of patients presenting to hospital with COVID-19 have bacterial co-infection. Procalcitonin testing may help identify patients for whom antibiotics should be prescribed or withheld. This study describes the use of procalcitonin in English and Welsh hospitals during the first wave of the COVID-19 pandemic. A web-based survey of antimicrobial leads gathered data about the use of procalcitonin testing. Responses were received from 148/151 (98%) eligible hospitals. During the first wave of the COVID-19 pandemic, there was widespread introduction and expansion of PCT use in NHS hospitals. The number of hospitals using PCT in emergency/acute admissions rose from 17 (11%) to 74/146 (50.7%) and use in Intensive Care Units (ICU) increased from 70 (47.6%) to 124/147 (84.4%). This increase happened predominantly in March and April 2020, preceding NICE guidance. Approximately half of hospitals used PCT as a single test to guide decisions to discontinue antibiotics and half used repeated measurements. There was marked variation in the thresholds used for empiric antibiotic cessation and guidance about interpretation of values. Procalcitonin testing has been widely adopted in the NHS during the COVID-19 pandemic in an unevidenced, heterogeneous way and in conflict with relevant NICE guidance. Further research is needed urgently that assesses the impact of this change on antibiotic prescribing and patient safety.

Keywords: COVID-19; antibiotic; procalcitonin; stewardship.

PubMed Disclaimer

Conflict of interest statement

J.A.T.S. has current research funding relating to diagnostic testing from NIHR, MRC, EPSRC, Wellcome Trust, and Leeds Cares. Within the last 5 years, J.S. has been involved in research funded by Pfizer, Astellas, and Merck Sharp and Dohme. N.P. has received honoraria from Thermofisher. P.D. is ADAPT sepsis Chief Investigator. M.J.L., J.E., P.H., S.T. are investigators on PRONTO. M.A. has received lecturing fees from Pfizer, and lecturing fees from Shionogi, H.D.R. U.K. P.P. E.C. E.T.J. investigators on PRONTO, BATCH, PRECISE. T.H. I.M., investigators on ADAPT (RISC-sepsis) B.S. supported by the NIHR In Vitro diagnostics Co-operative. T.S., D.P., S.B., M.O., H.P., D.S., R.W., L.B.H., S.H. none to declare.

Figures

Figure 1
Figure 1
Changed use of PCT testing at acute NHS hospitals in England and Wales. (A) Weekly number of hospitals using procalcitonin (PCT) on intensive care unit (ICU) (-•-) and Emergency Department (ED)/Acute Medical Unit (AMU) (-•-). For reference, the time course of the COVID-19 pandemic first wave in England is shown as weekly number of PCR positive cases (-). NG173 = National Institute for Health and Care Excellence (NICE) COVID-19 rapid guideline NG173: [9] Data extracted from Public Health England (PHE) national COVID surveillance reports available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/916994/COVID19_Weekly_Report_09_September_2020.pdf (accessed on 21 February 2021). (B). Breakdown of changes in PCT use on ICU and ED/AMU at 148 hospitals over the course of the pandemic first wave.
Figure 2
Figure 2
Perceived usefulness of procalcitonin (PCT) in relation to how it was used in practice.

References

    1. World Health Organisation Weekly Operational Update on COVID-19-8 February 2021. [(accessed on 23 March 2021)]; Available online: https://www.who.int/publications/m/item/weekly-operational-update-on-cov....
    1. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648. - DOI - PubMed
    1. Gov.UK Coronovirus (COVID-19) in the UK. [(accessed on 25 February 2021)]; Available online: https://coronavirus.data.gov.uk/details/healthcare.
    1. Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., Satta G., Cooke G., Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin. Infect. Dis. 2020;71:2459–2468. doi: 10.1093/cid/ciaa530. - DOI - PMC - PubMed
    1. Martén-Loeches I.M.D.P., Sanchez-Corral A.M.D., Diaz E.M.D.P., Granada R.M.M.D., Zaragoza R.M.D., Villavicencio C.M.D., Albaya A.M.D., Cerdá E.M.D., Catalán R.M.M.D., Luque P.M.D., et al. Community-Acquired Respiratory Coinfection in Critically Ill Patients With Pandemic 2009 Influenza A(H1N1) Virus. Chest. 2011;139:555–562. doi: 10.1378/chest.10-1396. - DOI - PubMed

LinkOut - more resources